Delivery Order SPE2DB24D2100-SPE2DB25FBGLZ
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $17,574.08 to AmerisourceBergen Drug Corp for the supply of Ozempic 0.25-0.5 mg/dose pens (3ml) on September 9, 2025, with completion targeted for September 10, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The pharmaceutical product will be supplied from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a $37,417.19 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens in 3 mL formulations, with completion targeted for September 15, 2025. This competitively awarded, non-set-aside contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's broader relationship...
- The Defense Logistics Agency awarded a delivery order valued at $3,919.58 to AmerisourceBergen Drug Corp for the supply of Ozempic 0.25-0.5 mg/dose pens (3 mL) on July 24, 2025, with a completion date of July 25, 2025. This competitive award was issued under a firm fixed-price contract type with no set-aside designation. The product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order...
- The Defense Logistics Agency awarded a $15,368 delivery order to AmerisourceBergen Drug Corp for Ozempic 0.25-0.5 mg/dose pens (3ml) on May 2, 2025, with completion targeted for May 5, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $19,861.09 to AmerisourceBergen Drug Corp for the supply of Ozempic (0.25-0.5 mg/dose) pens in 3ml quantities. This competitive award, issued on August 8, 2025, with an ultimate completion date of August 11, 2025, was made without set-aside designation under a firm fixed-price contract type. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical...
- The Defense Logistics Agency awarded a $9,656.92 delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Ozempic (0.25-0.5 mg/dose) pens in 3 ml quantities. The contract represents a firm fixed price delivery order with an ultimate completion date of September 9, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This award was competitively awarded with no set-aside designation, reflecting AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $2,852.74 to AmerisourceBergen Drug Corp for the supply of Ozempic 0.25-0.5 mg/dose pens (3ml) under a firm fixed price contract. The award was made on August 27, 2025, with an ultimate completion date of August 28, 2025, and represents a non-set-aside competitive procurement. This delivery order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic 0.25-0.5 mg/dose pens (3 mL) under a firm fixed-price contract valued at $11,505.44. The award was made on July 24, 2025, with an ultimate completion date of July 25, 2025, and represents a non-set-aside competitive procurement. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp valued at $12,273.77 for the supply of Ozempic 0.25-0.5 mg/dose pens (3 mL) under a firm fixed-price contract with an ultimate completion date of July 31, 2025. This non-set-aside competitive award represents a child delivery order issued against AmerisourceBergen's substantial Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic 0.25-0.5 mg/dose pens (3ml) with a ceiling value of $10,435.08. This firm fixed-price delivery order, issued on August 21, 2025, with an ultimate completion date of August 22, 2025, represents a competitive award with no set-aside designation. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, the location of AmerisourceBergen's corporate headquarters and...
- SPE2DB24D2100Indefinite Delivery Contract
- SPE2DB24D2100-SPE2DB25FBGLZDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $216,305.76 to AmerisourceBergen Drug Corp for the supply of Ozempic 0.25-0.5 mg/dose pens (3ml) on September 18, 2025, with completion targeted for September 19, 2025. This competitively awarded, non-set-aside contract employs firm fixed pricing and is classified as a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through December 2026. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania, will perform fulfillment from its corporate office location in that same city. This delivery order represents a routine pharmaceutical procurement supporting the Defense Health Agency and broader military healthcare systems. AmerisourceBergen's role as a Pharmaceutical Prime Vendor through the SPE2DX vehicle enables it to supply critical diabetes medications and other pharmaceutical products to federal medical supply chains worldwide. The award reflects the company's established capability to meet federal procurement requirements through open competition, consistent with DLA's strategy of utilizing multiple qualified pharmaceutical vendors to ensure reliable supply of medications across the global defense healthcare enterprise.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $216.3k | 9/18/25 |